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tively in particular conditions a PI (Protease 
Inhibitor), boosted with ritonavir or cobici-
stat, as a standard treatment for HIV-infected 
patients [1]. These combination therapies are 
defined by the term cART (combination Anti-
Retroviral Therapy) [1].
Despite the great progress achieved by the 
pharmacological research, a therapy capable 
of eradicating HIV remains a mirage. It is 
therefore crucial to maintain the effective-
ness over time of the antiretroviral treatment 
adopted, despite the fact that the administra-
tion of a cART regimen could, in the medium 
to long term, result in the reduction in adher-
ence, the onset of toxicity, the aggravation of 
IntroductIon
The Continuum of Care in the management 
of HIV infection (Human Immunodeficiency 
Virus) describes a patient care pathway that 
begins with the diagnosis, and then continues 
with the choice of therapy (engagement in 
care) and its maintenance (retention in care). 
The selection of the antiretroviral therapy is 
the foundation of this pathway. The latest 
Italian Guidelines recommend the combina-
tion of two NRTIs (Nucleoside Reverse Tran-
scriptase Inhibitor) with a INI (INtegrase 
Inhibitor) or a NNRTI (Non-Nucleoside 
Reverse Transcriptase Inhibitor), or alterna-
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AbstrAct
BACKGROUND: In order to reduce/prevent combination Anti-Retroviral Therapy (cART)-related toxicity, while main-
taining its therapeutic effectiveness over time, the optimization of the antiretroviral therapy could be performed.
AIM: To estimate the economic impact on the Italian National Health Service (NHS) of a cART optimization pathway as 
maintenance therapy in HIV-1 infected patients over one-year period.
METHODS: Patient data were retrieved from the electronic medical record system in use (year 2015) in a reference HIV 
Center in Northern Italy. The analysis considered naïve patients and non-naïve patients. To estimate the actual ART ex-
penditure charged to the Center we calculated the cost of cART received during 12 months for each patient. Subsequently, 
referring to the same patients, a "potential" cART expenditure was estimated. This potential expenditure was estimated 
taking in consideration the adoption of a specific optimization pathway aimed at maintaining over the time the cART ef-
ficacy. Lastly, to assess the sustainability of the optimization pathway, we compared the actual cART expenditure with the 
potential one. We considered only drug costs (ex-factory prices, included all discounts and VAT) from the perspective of 
the Italian NHS.
RESULTS: In the 2015, the total expenditure for 564 enrolled HIV-1 patients treated with cART was € 4,042,983. The mean 
treatment cost per patient was € 7,168. If the Center adopted a specific optimization pathway, the total expenditure would 
be € 3,914,855 (-€ 128,128).
CONCLUSIONS: From the Italian NHS’s perspective, the adoption of a specific cART optimization pathway represents a 
cost-saving option as maintenance antiretroviral therapy in HIV-1 infected patients. 
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already present comorbidities, an increase in 
the risk of pharmacological interactions with 
concomitant therapies due to contingent co-
morbidities, or the loss of strength/evidence 
(recommendation) of the regimen adminis-
tered [1-3].
In order to reduce/prevent cART-related tox-
icity, while maintaining its therapeutic effec-
tiveness over time, the optimization of the 
antiretroviral therapy could be performed, as 
indicated in the Italian Guidelines [1]. Three 
optimization options can be assumed. The 
first involves the reduction in the number of 
antiretroviral regimens administered; in this 
case there would be a switch from a three-
drug (triple) to a two-drug (double) therapy. 
The second option is not aimed at changing 
the current therapy, but to reduce the number 
of daily doses/administrations and/or daily 
tablets. The third option, finally, involves the 
replacement of the current regimen with oth-
er regimens consisting of the same number of 
drugs or more. For each of the three options, 
the modification of the cART therapy should 
occur under virological suppression (HIV-
RNA < 50 copies/ml) [1].
Without addressing here the issue of the 
clinical implications – since they are widely 
discussed in the Italian Guidelines, to which 
it is hereby referred to [1] – the optimization 
of the cART regimens presents a further is-
sue, concerning economic sustainability. If, 
as seen from past experience [4], the switch 
from a three-drug (triple) to a two-drug (dou-
ble) therapy can result in a reduction in the 
expenditure on antiretroviral drugs, the same 
cannot be said for the other optimization path-
ways presented. For example, with regard to 
the potential cardiovascular and/or metabolic 
toxicity associated with current antiretrovi-
ral regimens, the Italian Guidelines suggest 
instead to preferably adopt regimens based 
on integrase inhibitors (and not on protease 
inhibitors), without however saying anything 
about their economic sustainability [1].
The objective of this analysis is therefore to 
ascertain whether and how a cART optimiza-
tion pathway can, as a whole, be sustainable 
for the Italian National Health Service.
Methods
Analysis design
An observational, retrospective and non-in-
terventional analysis was conducted. The sta-
tistical source consists of all HIV-diagnosed 
patients (hereinafter referred to as “patients 
treated”, or even more concisely as “pa-
tients”) of the Infectious Diseases Operating 
Unit of the Hospital “G.B. Rossi” in Verona 
(hereinafter referred to as the “Center”), who 
received an antiretroviral therapy during the 
period 1st January- 31st December 2015.
The patients (who in the analysis were iden-
tified by encrypted – and therefore strictly 
anonymous – codes) were classified into two 
groups: i) naïve, i.e. patients who started the 
antiretroviral treatment during the observa-
tion year, and ii) non-naïve, i.e. patients who 
were already being treated with an antiretro-
viral regimen.
For each of them – characterized by the main 
demographic (mean age, gender, etc.) and 
clinical variables (virological suppression, 
resistances, HCV, HBV, etc.) – the antiret-
roviral therapy received during the last 12 
months was identified, in order to calculate 
its actual pharmaceutical cost borne by the 
Center. Subsequently, with reference to the 
same patients, an antiretroviral expenditure 
was estimated; this was defined as “poten-
tial”, because it was due to the adoption of 
a specific optimization pathway aimed at im-
proving the maintenance of the antiretroviral 
therapy effectiveness over time [1]. The com-
parison between actual and potential spend-
ing finally allowed to express a judgment on 
the sustainability (or not) of the optimization 
pathway with regard to the cART regimens 
administered during the year 2015.
Optimization pathway
The optimization pathway suggested here 
was constructed in accordance with the indi-
cations of the Italian Guidelines [1]. Two op-
timization options were assumed, in chrono-
logical order. The first is the switch from a 
three-drug to a two-drug regimen. Based on 
the results of a previous experience gained 
by the Center, the two-drug regimen selected 
was the combination nevirapine 400 mg/day 
(NNRTI) and raltegravir 400 mg bis in die, 
BID (INI) [4]. The therapy switch could only 
be executed for patients who had been in vi-
rological suppression (viral load < 50 copies/
ml) for at least 12 months, without any prior 
exposure to an INI, with no NNRTI-associ-
ated resistance mutations and with a toxicity 
(dyslipidemia and/or chronic renal failure) 
correlated with the therapy received.
Since – in view of the potential cardiovas-
cular and/or metabolic toxicity of the cur-
rent cART regimens – the Italian Guidelines 
suggest instead to preferably adopt regimens 
based on INIs, the second optimization path-
way option involves, for the subjects who do 
not fall under the first option, the substitu-
tion of the toxic regimens with others, less 
toxic [1]. The identification of the potentially 
toxic regimens was performed by analyzing 
the cART therapy received by each patient. 
Then, based on the history of cART received 
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In case of switch from a three-drug regimen 
to that with nevirapine/raltegravir, for the lat-
ter a mean annual treatment cost of € 5,566 
was considered [4]. In case of replacement 
of the potentially toxic antiretroviral regimen 
(cardiovascular and/or metabolic effect), an 
average annual cost calculated on the basis 
of the antiretroviral regimens suggested as al-
ternatives was estimated for each patient [1].
Data analysis
Quantitative variables have been described as 
mean value (± standard deviation), categori-
cal variables as numeric value (percentage). 
The significance of the differences between 
the data found/processed was verified by 
applying the (two-tier) Student’s t-test. The 
analysis was supported by Microsoft® Ex-
cel® for Windows® (Microsoft Corporation, 
and the indications suggested by the Italian 
Guidelines, a number of possible alternative 
regimens were assumed [1]. In this case too, 
the therapy switch had to take place in con-
ditions of virological suppression maintained 
for at least one year. Naïve patients were not 
included in the optimization pathway because 
they have not been in virological suppression 
for at least 12 months since they received the 
first antiretroviral treatment during the obser-
vation year (2015).
Treatment cost
The two expenditures – actual and potential 
– for the antiretroviral drugs were calculated 
considering the purchase prices, net of all 
(mandatory and not) discounts and including 
VAT, borne by the Hospital Pharmacy of the 
Center. All costs are referred to the year 2015. 
Characteristics naïve non naïve Total
Patients, n. 34 530 564
Mean age, years (± SD) 41.9 (± 9.8) 49.0 (± 9.7) 48.5 (± 9.9)
Time to diagnosis, years (± SD) 5.2 (± 5.1) 13.7 (± 8.1) 13.2 (± 8.2)
Previous treatments failed, n. (± SD) 0.0 (± 0.0) 0.6 (± 1.2) 0.6 (± 1.2)
Virological suppression1, n. (%)
 • For more than 1 year 0 (0.0) 405 (76.4) 405 (71.8)
 • For less than 1 year 1 (2.9) 16 (3.0) 17 (3.0)
 • No 33 (97.1) 109 (20.6) 142 (25.2)
CD4, n. (± SD) 394.1 (± 179.0) 625.2 (± 283.3) 611.2 (± 283.4)
%CD4, n. (± SD) 20.3% (± 9.4%) 28.9% (± 9.5%) 28.4% (± 9.7%)
Resistances, n. (%)
 • No 24 (70.6) 168 (31.7) 192 (34.0)
 • Resistance/partial resistance 4 (11.8) 127 (24.0) 131 (23.2)
 • Test not performed/unavailable 6 (17.6) 235 (44.3) 241 (42.7)
HLA B5701, n. (%)
 • Positive 1 (2.9) 8 (1.5) 9 (1.6)
 • Negative 20 (58.8) 344 (64.9) 364 (64.5)
 • Test not performed/unavailable 13 (38.2) 178 (33.6) 191 (33.9)
Smoker, n. (%) 13 (38.2) 151 (28.5) 164 (29.1)
Systolic pressure, mmHg (± SD) 126.0 (± 10.1) 128.9 (± 11.5) 128.8 (± 11.5)
Diastolic pressure, mmHg (± SD) 80.7 (± 5.1) 82.5 (± 7.4) 82.4 (± 7.3)
HCV, n. (%) 3 (8.8) 134 (25.3) 137 (24.3)
HBV, n. (%) 0 (0.0) 18 (3.4) 18 (3.2)
Dyslipidemia, n. (%) 6 (17.6) 189 (35.7) 195 (34.6)
Total cholesterol, mg/dl (± SD) 176.0 (± 42.3) 188.8 (± 41.4) 188.0 (± 41.5)
HDL cholesterol, mg/dl (± SD) 47.0 (± 14.6) 51.8 (± 17.4) 51.5 (± 17.3)
Chronic renal failure, n. (%) 1 (2.9) 20 (3.8) 21 (3.7)
Densitometry, n. (%)
 • No 34 (100.0) 465 (87.7) 499 (88.5)
 • Osteopenia 0 (0.0) 50 (9.4) 50 (8.9)
 • Osteoporosis 0 (0.0) 15 (2.8) 15 (2.7)
Previous CVD event, n. (%) 0 (0.0) 23 (4.3) 23 (4.1)
Dyslipidemia or osteoporosis drugs, n. (%) 1 (2.9) 192 (36.2) 193 (34.2)
Hypertension drugs, n. (%) 1 (2.9) 96 (18.1) 97 (17.2)
Table I. Main demographic and clinical characteristics of the patients enrolled
1 HIV-RNA < 50 copies/ml
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virapine/raltegravir (Figure 1). Of these, 53 
were in treatment with 2 NRTIs + 1 PI, 51 
with 2 NRTIs + 1 NNRTI and 7 received 3 
NRTIs. All 111 patients had been in viro-
logical suppression for at least 12 months, 
without any NNRTI- or INI-associated 
resistance mutations. Each of them also 
presented a toxicity due to dyslipidemia 
(95.5%, n. = 106) and/or chronic renal fail-
ure (7.2%, n. = 8).
Of the remaining 453 patients, 176 were 
the subjects for whom it would have been 
desirable to replace the adopted regimen 
(Table III), characterized by a potential 
cardiovascular and/or metabolic toxicity, 
with one of those indicated in the Italian 
Guidelines (Table IV). On average, about 4 
alternative regimens for each patient were 
provided for.
Figure 1. Optimization pathway
Agents ART Regimens
Patients
n. % Mean cost (€)
Atazanavir Maraviroc Ritonavir 1 CCR5 + 1 PI 1 0.6 15,134
Raltegravir Lopinavir/Ritonavir 1 INI + 1 PI 1 0.6 3,706
Raltegravir Darunavir Ritonavir 1 INI + 1 PI 7 4.0 11,224
Darunavir Ritonavir 1 INI + 1 PI 2 1.1 12,203
Tenofovir Raltegravir Atazanavir Ritonavir 1 NRTI + 1 INI + 1 PI 1 0.6 11,911
Lamivudine Lopinavir/Ritonavir 1 NRTI + 1 PI 1 0.6 2,290
Lamivudine Darunavir Ritonavir 1 NRTI + 1 PI 1 0.6 3,782
Lamivudine Atazanavir Ritonavir 1 NRTI + 1 PI 11 6.3 6,209
Lamivudine Fosamprenavir Ritonavir 1 NRTI + 1 PI 3 1.7 5,272
Lopinavir/Ritonavir 1 PI 5 2.8 3,862
Darunavir Raltegravir Ritonavir 1 PI 4 2.3 4,801
Fosamprenavir Ritonavir 1 PI 3 1.7 4,054
Zidovudine/Lamivudine 2 NRTI 2 1.1 211
Abacavir/Lamivudine Raltegravir 2 NRTI + 1 INI 13 7.4 9,723
Abacavir/Lamivudine Nevirapine 2 NRTI + 1 NNRTI 20 11.4 5,688
Abacavir/Lamivudine Efavirenz 2 NRTI + 1 NNRTI 10 5.7 5,537
Zidovudine/Lamivudine Fosamprenavir Ritonavir 2 NRTI + 1 PI 2 1.1 4,118
Abacavir/Lamivudine Lopinavir/Ritonavir 2 NRTI + 1 PI 2 1.1 8,831
Abacavir/Lamivudine Darunavir Ritonavir 2 NRTI + 1 PI 5 2.8 8,869
Abacavir/Lamivudine Atazanavir 2 NRTI + 1 PI 25 14.2 10,416
Abacavir/Lamivudine Atazanavir Ritonavir 2 NRTI + 1 PI 8 4.5 8,225
Abacavir/Lamivudine Fosamprenavir 2 NRTI + 1 PI 3 1.7 9,950
Abacavir/Lamivudine Fosamprenavir Ritonavir 2 NRTI + 1 PI 5 2.8 8,447
Tenofovir/Emtricitabine Lopinavir/Ritonavir 2 NRTI + 1 PI 5 2.8 9,558
Tenofovir/Emtricitabine Darunavir Ritonavir 2 NRTI + 1 PI 3 1.7 8,826
Tenofovir/Emtricitabine Atazanavir Ritonavir 2 NRTI + 1 PI 10 5.7 8,968
Tenofovir/Emtricitabine Fosamprenavir Ritonavir 2 NRTI + 1 PI 2 1.1 9,174
Zidovudine/Lamivudine Tenofovir 3 NRTI 2 1.1 3,535
Abacavir/Lamivudine Rilpivirine 3 NRTI 9 5.1 7,001
Abacavir/Lamivudine Tenofovir 3 NRTI 1 0.6 7,864
Zidovudine/Lamivudine/Abacavir 3 NRTI 9 5.1 6,019
Total  176 100 7,690
Table III. Regimens characterized by a potential cardiovascular and/or metabolic toxicity [1]
ral drugs (naïve: 67.6%, non-naïve: 77.0%) 
(Table II). The most frequently used regi-
mens were 2 NRTIs + 1 PI (n. = 186; 33.0%; 
€ 9,077) and 2 NRTIs + 1 NNRTI (n. = 165; 
29.3%; € 6,076). 46.6% of the regimens ad-
ministered contained a PI, while 15.2% con-
tained an INI. The average duration of treat-
ment during the year for naïve patients was 
5.4 (± 3.2) months, whereas for non-naïve 
patients it was 12 months (all non-naïve pa-
tients were in continuous treatment for the 12 
months of observation).
Optimization pathway
Following the chronological sequence of 
the potential therapy switches assumed 
within the cART optimization pathway, in 
111 patients it would have been possible 
to switch from a three-drug regimen to ne-
ART regimens
Patients
naïve non-naïve Total
n. % Mean cost (€) n. % Mean cost (€) n. % Mean cost (€)
2 NRTI + 1 PI1 5 14.7 4,811 181 34.2 9,195 186 33.0 9,077
2 NRTI + 1 NNRTI1 16 47.1 3,092 149 28.1 6,397 165 29.3 6,076
3 NRTI1 2 5.9 1,518 42 7.9 6,478 44 7.8 6,252
2 NRTI + 1 INI1 - - - 35 6.6 10,119 35 6.2 10,119
1 NRTI + 1 PI 1 2.9 2,107 34 6.4 5,773 35 6.2 5,668
1 PI - - - 27 5.1 4,455 27 4.8 4,455
1 NNRTI + 1 INI - - - 13 2.5 4,657 13 2.3 4,657
1 INI + 1 PI - - - 13 2.5 10,571 13 2.3 10,571
1 NRTI + 1 INI - - - 11 2.1 6,388 13 2.3 3,960
2 NRTI - - - 10 1.9 3,768 11 2.0 6,388
1 NRTI + 1 NNRTI - - - 9 1.7 2,146 10 1.8 3,768
1 INI 10 29.4 2,960 3 0.6 7,295 9 1.6 2,146
1 NRTI + 1 INI + 1 PI - - - 1 0.2 11,911 1 0.2 11,911
1 NNRTI - - - 1 0.2 432 1 0.2 432
1 CCR5 + 1 PI - - - 1 0.2 15,134 1 0.2 15,134
Total 34 100 3,184 530 100 7,424 564 100 7,424
Table II. cART regimens administered
1 Highly Active Anti-Retroviral Therapy (HAART) regimens
the main demographic and clinical character-
istics of the patients enrolled. The mean age 
was 48.5 (± 9.9) years, with an average dura-
tion of HIV infection at diagnosis of 13.2 (± 
8.2) years. 71.8% (n. = 405) of patients had 
been in virological suppression for at least 12 
months.
cART regimens
76.4% (n. = 431) of patients received a regi-
men consisting of at least three antiretrovi-
Seattle, WA, USA) and SPSS® 13.0 for Win-
dows® (SPSS Inc., Chicago, IL, USA).
results
Characteristics of the sample
Overall, during the year 2015, 564 HIV-di-
agnosed patients under treatment with cART 
regimens were referred to the Center. Of 
these, 6% (n. = 34) started antiretroviral ther-
apy in 2015 (naïve patients). Table I shows 
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virapine/raltegravir (Figure 1). Of these, 53 
were in treatment with 2 NRTIs + 1 PI, 51 
with 2 NRTIs + 1 NNRTI and 7 received 3 
NRTIs. All 111 patients had been in viro-
logical suppression for at least 12 months, 
without any NNRTI- or INI-associated 
resistance mutations. Each of them also 
presented a toxicity due to dyslipidemia 
(95.5%, n. = 106) and/or chronic renal fail-
ure (7.2%, n. = 8).
Of the remaining 453 patients, 176 were 
the subjects for whom it would have been 
desirable to replace the adopted regimen 
(Table III), characterized by a potential 
cardiovascular and/or metabolic toxicity, 
with one of those indicated in the Italian 
Guidelines (Table IV). On average, about 4 
alternative regimens for each patient were 
provided for.
Figure 1. Optimization pathway
Agents ART Regimens
Patients
n. % Mean cost (€)
Atazanavir Maraviroc Ritonavir 1 CCR5 + 1 PI 1 0.6 15,134
Raltegravir Lopinavir/Ritonavir 1 INI + 1 PI 1 0.6 3,706
Raltegravir Darunavir Ritonavir 1 INI + 1 PI 7 4.0 11,224
Darunavir Ritonavir 1 INI + 1 PI 2 1.1 12,203
Tenofovir Raltegravir Atazanavir Ritonavir 1 NRTI + 1 INI + 1 PI 1 0.6 11,911
Lamivudine Lopinavir/Ritonavir 1 NRTI + 1 PI 1 0.6 2,290
Lamivudine Darunavir Ritonavir 1 NRTI + 1 PI 1 0.6 3,782
Lamivudine Atazanavir Ritonavir 1 NRTI + 1 PI 11 6.3 6,209
Lamivudine Fosamprenavir Ritonavir 1 NRTI + 1 PI 3 1.7 5,272
Lopinavir/Ritonavir 1 PI 5 2.8 3,862
Darunavir Raltegravir Ritonavir 1 PI 4 2.3 4,801
Fosamprenavir Ritonavir 1 PI 3 1.7 4,054
Zidovudine/Lamivudine 2 NRTI 2 1.1 211
Abacavir/Lamivudine Raltegravir 2 NRTI + 1 INI 13 7.4 9,723
Abacavir/Lamivudine Nevirapine 2 NRTI + 1 NNRTI 20 11.4 5,688
Abacavir/Lamivudine Efavirenz 2 NRTI + 1 NNRTI 10 5.7 5,537
Zidovudine/Lamivudine Fosamprenavir Ritonavir 2 NRTI + 1 PI 2 1.1 4,118
Abacavir/Lamivudine Lopinavir/Ritonavir 2 NRTI + 1 PI 2 1.1 8,831
Abacavir/Lamivudine Darunavir Ritonavir 2 NRTI + 1 PI 5 2.8 8,869
Abacavir/Lamivudine Atazanavir 2 NRTI + 1 PI 25 14.2 10,416
Abacavir/Lamivudine Atazanavir Ritonavir 2 NRTI + 1 PI 8 4.5 8,225
Abacavir/Lamivudine Fosamprenavir 2 NRTI + 1 PI 3 1.7 9,950
Abacavir/Lamivudine Fosamprenavir Ritonavir 2 NRTI + 1 PI 5 2.8 8,447
Tenofovir/Emtricitabine Lopinavir/Ritonavir 2 NRTI + 1 PI 5 2.8 9,558
Tenofovir/Emtricitabine Darunavir Ritonavir 2 NRTI + 1 PI 3 1.7 8,826
Tenofovir/Emtricitabine Atazanavir Ritonavir 2 NRTI + 1 PI 10 5.7 8,968
Tenofovir/Emtricitabine Fosamprenavir Ritonavir 2 NRTI + 1 PI 2 1.1 9,174
Zidovudine/Lamivudine Tenofovir 3 NRTI 2 1.1 3,535
Abacavir/Lamivudine Rilpivirine 3 NRTI 9 5.1 7,001
Abacavir/Lamivudine Tenofovir 3 NRTI 1 0.6 7,864
Zidovudine/Lamivudine/Abacavir 3 NRTI 9 5.1 6,019
Total  176 100 7,690
Table III. Regimens characterized by a potential cardiovascular and/or metabolic toxicity [1]
ral drugs (naïve: 67.6%, non-naïve: 77.0%) 
(Table II). The most frequently used regi-
mens were 2 NRTIs + 1 PI (n. = 186; 33.0%; 
€ 9,077) and 2 NRTIs + 1 NNRTI (n. = 165; 
29.3%; € 6,076). 46.6% of the regimens ad-
ministered contained a PI, while 15.2% con-
tained an INI. The average duration of treat-
ment during the year for naïve patients was 
5.4 (± 3.2) months, whereas for non-naïve 
patients it was 12 months (all non-naïve pa-
tients were in continuous treatment for the 12 
months of observation).
Optimization pathway
Following the chronological sequence of 
the potential therapy switches assumed 
within the cART optimization pathway, in 
111 patients it would have been possible 
to switch from a three-drug regimen to ne-
ART regimens
Patients
naïve non-naïve Total
n. % Mean cost (€) n. % Mean cost (€) n. % Mean cost (€)
2 NRTI + 1 PI1 5 14.7 4,811 181 34.2 9,195 186 33.0 9,077
2 NRTI + 1 NNRTI1 16 47.1 3,092 149 28.1 6,397 165 29.3 6,076
3 NRTI1 2 5.9 1,518 42 7.9 6,478 44 7.8 6,252
2 NRTI + 1 INI1 - - - 35 6.6 10,119 35 6.2 10,119
1 NRTI + 1 PI 1 2.9 2,107 34 6.4 5,773 35 6.2 5,668
1 PI - - - 27 5.1 4,455 27 4.8 4,455
1 NNRTI + 1 INI - - - 13 2.5 4,657 13 2.3 4,657
1 INI + 1 PI - - - 13 2.5 10,571 13 2.3 10,571
1 NRTI + 1 INI - - - 11 2.1 6,388 13 2.3 3,960
2 NRTI - - - 10 1.9 3,768 11 2.0 6,388
1 NRTI + 1 NNRTI - - - 9 1.7 2,146 10 1.8 3,768
1 INI 10 29.4 2,960 3 0.6 7,295 9 1.6 2,146
1 NRTI + 1 INI + 1 PI - - - 1 0.2 11,911 1 0.2 11,911
1 NNRTI - - - 1 0.2 432 1 0.2 432
1 CCR5 + 1 PI - - - 1 0.2 15,134 1 0.2 15,134
Total 34 100 3,184 530 100 7,424 564 100 7,424
Table II. cART regimens administered
1 Highly Active Anti-Retroviral Therapy (HAART) regimens
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of toxicity, with one of those set out in the 
Italian Guidelines amounted to € 1,353,474, 
with an average cost of € 7,690 ± 2,634) 
(Table V). Approximately 70% of these regi-
mens consisted of 2 NRTIs + 1 PI (n. = 70; 
€ 9,297 ± 1,392), 2 NRTIs + 1 NNRTI (n. = 
30; € 5,638 ± 864) and 3 NRTIs (n. = 21; € 
6,291 ± 1,151).
Finally, the other patients maintaining their 
current antiretroviral regimen without any 
change determined a cost of € 1,720,943, 
with an average cost of € 7,082 ± 2,473 (Ta-
ble V).
Potential pharmaceutical 
expenditure
Besides reporting the actual expenditure data 
for the antiretroviral drugs for the year 2015, 
Table V indicates the estimate for the same 
expenditure in light of the proposed optimi-
zation path (potential scenario). The expen-
diture associated with naïve patients (patients 
who received the first treatment during 2015) 
remains exactly the same as that calculated 
for the actual scenario, since – by definition 
– naïve patients, not having been in virologi-
cal suppression for at least 12 months, cannot 
fall within the selection criteria adopted by 
the optimization path. Therefore, the finan-
cial impact would occur only on non-naïve 
patients. The potential switch from a three-
Patients n.
Treatment cost with cART (€) 
DeltaActual scenario Potential scenario
Total expenditure Average cost Total expenditure Average cost
Naïve 34 108,271 3,184 108,271 3,184 0
Non-naïve 530 3,934,712 7,424 3,806,584 7,182 - 128,128
 • switch from a three-drug 
to a two-drug regimen
111 860,295 7,750 617,826 5,566 - 242,469
 • switch due to CV and/or 
metabolic toxicity
176 1,353,474 7,690 1,467,815 8,340 114,341
 • maintenance actual 
regimen
243 1,720,943 7,082 1,720,943 7,082 0
Total 564 4,042,983 7,168 3,914,855 6,941 - 128,128
Table V. Pharmaceutical expenditure charged to the Center: actual vs potential scenario
Current pharmaceutical expenditure
In 2015, the actual pharmaceutical expen-
diture borne by the Center and generated 
by the 564 patients receiving antiretroviral 
drugs was € 4,042,983, of which € 108,271 
for naïve patients and € 3,934,712 for non-
naïve patients (Table V). The mean phar-
macological treatment cost was € 7,168 ± € 
2,605 (naïve patient: € 3,184 ± 2,003; non-
naïve patient € 7,424 ± 2,426). The pharma-
ceutical expenditure generated by the 111 
patients receiving a triple therapy who could 
be treated with the nevirapine/raltegravir 
regimen was € 860,295, with a mean cost of 
€ 7,750 ± 1,827 (Table V). The 2 NRTIs + 
1 PI combination resulted in the highest av-
erage cost (€ 9,139 ± 1,405), followed by 3 
NRTIs (€ 7,030, ± 1,268) and 2 NRTIs + 1 
NNRTI (€ 6,406, ± 1,066). Cost differences 
between the 2 NRTIs + 1 PI and the other 
two regimens were statistically significant (p 
< 0.001), while that between 3 NRTIs and 2 
NRTIs + 1 NNRTI was not (p = 0.25). If costs 
at the individual patient level are analyzed, in 
13 cases only (11.7%) the use of a three-drug 
regimen resulted in an annual cost (range: € 
2,328-€ 5,408) lower than that of the nevirap-
ine/raltegravir regimen (€ 5,566).
However, the drug expenditure for the 176 
patients for whom it would have been desir-
able to replace the current regimen at risk 
Agents ART Regimens
Patients
n. % Mean cost (€)
Dolutegravir Rilpivirine 1NNRTI + INI 68 9.8 8,712
Rilpivirine Darunavir Ritonavir 1NNRTI + PI/r 36 5.2 7,243
Lamivudine Dolutegravir 1NRTI + INI 67 9.7 6,086
Lamivudine Atazanavir Ritonavir 1NRTI + PI/r 42 6.1 4,440
Tenofovir/emtricitabine 2NRTI 2 0.3 5,267
Tenofovir/emtricitabine Raltegravir 2NRTI + INI 68 9.8 10,534
Tenofovir/emtricitabine Dolutegravir 2NRTI + INI 55 7.9 11,209
Tenofovir/emtricitabine Rilpivirine 2NRTI + NNRTI 63 9.1 8,036
Tenofovir/emtricitabine Nevirapine 2NRTI + NNRTI 62 8.9 5,550
Tenofovir/emtricitabine Efavirenz 2NRTI + NNRTI 10 1.4 5,699
Tenofovir/emtricitabine Nevirapine 2NRTI + NNRTI 9 1.3 7,411
Tenofovir/emtricitabine Atazanavir 2NRTI + PI 77 11.1 11,306
Tenofovir/emtricitabine Fosamprenavir 2NRTI + PI 3 0.4 10,678
Tenofovir/emtricitabine Darunavir Ritonavir 2NRTI + PI/r 15 2.2 9,740
Tenofovir/emtricitabine Atazanavir Ritonavir 2NRTI + PI/r 31 4.5 9,563
Raltegravir Darunavir INI + PI 13 1.9 11,903
Raltegravir Darunavir Ritonavir INI + PI/r 27 3.9 12,203
Lamivudine Darunavir Ritonavir NRTI + PI/r 25 3.6 4,618
Darunavir Ritonavir PI/r 8 1.2 4,474
Atazanavir Ritonavir PI/r 12 1.7 4,296
Total 693 100.0 8,365
Table IV. Alternative regimens in case of switch due to cardiovascular and/or metabolic toxicity [1]
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drug to a two-drug regimen, but also the sus-
tainability, on the part of the Center, of an 
antiretroviral therapy management pathway 
which, in the face of the potential cardiovas-
cular and/or metabolic toxicities associated 
with current antiretroviral regimens, sug-
gested instead, according to the indications 
of the Italian Guidelines [1], to preferably 
adopt regimens based on integrase inhibitors.
In line with the previous analysis referred to 
the year 2014 [4], the first optimization path-
way option – namely the switch from a three-
drug to a two-drug regimen – would allow 
to reduce the Center-borne antiretroviral ex-
penditure by around € 242,000. This amount 
would allow the Center itself to cope with the 
increase in spending (around € 114,000) as-
sociated with the second option of the opti-
mization pathways – i.e. the replacement of 
potentially toxic regimens – as well as main-
taining a “comfort zone” (about € 128,000) 
with which to cope with any therapy switches 
that might become necessary.
The clinical rationale that makes it possible 
to switch from a three-drug regimen to the 
nevirapine/raltegravir combination relies on 
the results of two recent clinical trials [5,6]. 
drug to a two-drug regimen (nevirapine/
raltegravir) would result, for the 111 patients 
treated, in a reduction in the cost borne by 
the Hospital Pharmacy of the Center of € 
242,469. Conversely, the replacement of the 
regimens at risk of (cardiovascular and/or 
metabolic) toxicity with one of those indicat-
ed in the Italian Guidelines would cause, for 
the 176 patients treated, a potential increase 
in the cost borne by the Hospital Pharmacy of 
the Center of € 114,341. The average annual 
cost associated with these alternative regi-
mens was € 8,340 ± 2,000.
Overall, the adoption of the optimization 
pathway would result in a reduction in cART 
drug costs of € 128,128 (-3.2%) (Table V and 
Figure 2).
dIscussIon
The added value of this retrospective obser-
vational analysis – compared to the one pre-
viously conducted, again with reference to 
the Infectious Diseases Operating Unit of the 
Hospital “G.B. Rossi” in Verona [4] – con-
sists in the fact that it assessed not only the 
financial impact of the switch from a three-
Figure 2. Financial impact of the optimization pathway (potential vs current scenario)
of toxicity, with one of those set out in the 
Italian Guidelines amounted to € 1,353,474, 
with an average cost of € 7,690 ± 2,634) 
(Table V). Approximately 70% of these regi-
mens consisted of 2 NRTIs + 1 PI (n. = 70; 
€ 9,297 ± 1,392), 2 NRTIs + 1 NNRTI (n. = 
30; € 5,638 ± 864) and 3 NRTIs (n. = 21; € 
6,291 ± 1,151).
Finally, the other patients maintaining their 
current antiretroviral regimen without any 
change determined a cost of € 1,720,943, 
with an average cost of € 7,082 ± 2,473 (Ta-
ble V).
Potential pharmaceutical 
expenditure
Besides reporting the actual expenditure data 
for the antiretroviral drugs for the year 2015, 
Table V indicates the estimate for the same 
expenditure in light of the proposed optimi-
zation path (potential scenario). The expen-
diture associated with naïve patients (patients 
who received the first treatment during 2015) 
remains exactly the same as that calculated 
for the actual scenario, since – by definition 
– naïve patients, not having been in virologi-
cal suppression for at least 12 months, cannot 
fall within the selection criteria adopted by 
the optimization path. Therefore, the finan-
cial impact would occur only on non-naïve 
patients. The potential switch from a three-
Patients n.
Treatment cost with cART (€) 
DeltaActual scenario Potential scenario
Total expenditure Average cost Total expenditure Average cost
Naïve 34 108,271 3,184 108,271 3,184 0
Non-naïve 530 3,934,712 7,424 3,806,584 7,182 - 128,128
 • switch from a three-drug 
to a two-drug regimen
111 860,295 7,750 617,826 5,566 - 242,469
 • switch due to CV and/or 
metabolic toxicity
176 1,353,474 7,690 1,467,815 8,340 114,341
 • maintenance actual 
regimen
243 1,720,943 7,082 1,720,943 7,082 0
Total 564 4,042,983 7,168 3,914,855 6,941 - 128,128
Table V. Pharmaceutical expenditure charged to the Center: actual vs potential scenario
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maximum cost of the alternatives indicated 
for each patient (€ 9,688), the optimization 
pathway would have resulted in an increase 
in the cost of the antiretroviral drugs borne 
by the Center of € 109,201. However, in the 
absence of the financial effect resulting from 
the switch from a three-drug to a two-drug 
regimen (-€ 242,469), this increase in expen-
diture for the Center would have been higher 
(€ 351,671).
Local cost containment HIV strategies has 
been investigated considering different ap-
proaches (i.e., generic drugs, switch from a 
three-drug to a two-drug regimen or mono-
therapies) and costs (cART, hospitalization, 
outpatient activities, adverse events’ manage-
ment). For this reason it is difficult to com-
pare the present results with those of already 
published studies. The analysis, conducted 
by Angeletti et al. [8], shows how the most 
cost containing strategy would be the use of 
generic drugs, followed by simplification to 
monotherapy. A second analysis investigated 
the budget impact of ART simplification to 
less drug regimens over a 3-year horizon 
(costs referred to 2013) [9]. The Authors 
considered 4 simplification scenarios: i) de-
intensifying only PI-based triple therapies 
over 1 year period ii) de-intensifying only PI-
based triple therapies over a 3-year period, 
iii) de-intensifying PI-based triple therapies 
and NRTIs + efavirenz over 1 year period and 
iv) de-intensifying PI-based triple therapies 
and NRTIs + efavirenz over a 3-year period. 
Over a 3-year period, ART cost decreased be-
tween € 23.1 million and € 44.3 million con-
sidering different scenarios. A third analysis 
was conducted to evaluating the impact of 
treatment simplification of atazanavir (ATV) 
+ ritonavir (r) + lamivudine (3TC) in viro-
logically suppressed patients receiving ATV 
+ r + 2 nucleoside reverse transcriptase in-
hibitors (NRTIs) [10]. The perspective of the 
Italian National Health Service (NHS) was 
considered. The antiretroviral treatment sim-
plification strategy considered would lead to 
lower costs for the Italian NHS in a 5-year 
time horizon between € -28.7 million and € 
-16.0 million.
Although the comparison sought to provide 
a realistic scenario of the economic impact 
following the adoption of a specific optimiza-
tion pathway for the cART regimens admin-
istered for the treatment of HIV patients with 
the aim of maintaining the therapeutic effec-
tiveness also over the long term, the results 
presented here must be interpreted in light of 
some observations.
First of all, the hypothesis of being able to 
administer the alternative regimens suggest-
ed by the optimization path to the same pa-
Both were conducted with the aim of evalu-
ating the efficacy of a dual therapy consist-
ing of 1 NNRTI + 1 INI in place of HAART 
regimens as maintenance treatment of HIV-
infected patients in virological suppression. 
During the period September 2009-January 
2012, all patients referred to the centers of 
Besançon and Nantes with HIV infection, 
with a viral load < 50 copies/ml for more 
than six months and without prior exposure 
to INIs were switched from a three-drug regi-
men to the combination nevirapine (400 mg/
day) and raltegravir (400 mg BID) [5]. The 
36 enrolled patients, followed for a maxi-
mum of three years, maintained a viral load 
< 50 copies/ml, without the occurrence of 
grade 3 or 4 adverse events [5]. The subse-
quent Italian study replicated and validated 
de facto the previous French analysis [6]. Af-
ter a 32-month median time, 89.6% of the 77 
patients enrolled in the nevirapine/raltegra-
vir regimen were in virological suppression, 
while 6.5% experienced a virologic failure 
and 3.9% discontinued the treatment due to 
adverse events (skin rash or hepatic toxicity) 
[6]. The results of these experiences show 
that, in a well-defined case record of patients, 
the switch to a nevirapine/raltegravir therapy 
allows the long-term maintenance of an ad-
equate virological suppression.
As indicated in the methods, the identifica-
tion of the toxic regimens was performed by 
examining at the individual patient level the 
regimen administered during the observation 
year. Table III details the regimens character-
ized by a risk of cardiovascular and/or meta-
bolic toxicity for the 176 subjects for whom it 
would have been possible to switch the thera-
py with a regimen characterized by a reduced 
risk of toxicity. 71.6% of these regimens (126 
out of 176) contain abacavir or lopinavir, the 
exposure to which is a predictor of cardiovas-
cular risk [7]. The alternative regimens, listed 
in Table IV and identified according to the in-
dications of the Italian Guidelines, have al-
ways been identified at the individual patient 
level. In 49.4% of cases (87 out of 176), only 
one alternative method was identified; in the 
remaining cases, the choice was assumed 
between multiple treatments with different 
treatment costs. In 28.4% of cases, the choice 
could fall on more than seven alternatives. 
For this reason, the economic impact associ-
ated with the switch to a low cardiovascular 
and/or metabolic toxicity regimen may be 
subject to variations. Had we considered, 
instead of the average cost, the minimum 
cost of the alternatives indicated for each 
patient (€ 6,888), the “comfort zone” would 
have increased to € 383,652 compared to the 
base case; whereas, had we considered the 
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tients treated in 2015 with cART drugs. This 
assumption is the basis of this analysis, since 
it was not possible to create a real control 
group treated with the alternative regimens 
hypothesized by the optimization pathway. 
In light of this necessary compromise, in ad-
dition to the effectiveness data reported in the 
literature [5,6] and by the Italian Guidelines 
[1], further criteria supporting the switch to 
an alternative antiretroviral regimen were 
sought. For example, in the switch towards 
a two-drug regimen, since this would reduce 
the risk of long-term toxicity [11-15], it was 
established that patients – besides being in 
virological suppression – had also to report a 
toxicity associated with the HAART therapy.
A second critical aspect may be represented 
by the average cost considered in order to 
enhance the nevirapine/raltegravir regimen, 
or the alternative ones (cardiovascular and/
or metabolic toxicity). Such average cost, 
in fact, does not derive from real-world 
consumption data, as was the case with the 
regimens actually administered by the Cen-
ter, but is based on the purchase cost of the 
molecules, borne by the Center’s pharmacy, 
and the relevant dosages indicated in the lit-
erature, assuming that the duration of treat-
ment is one year. In actual fact, however, this 
choice may have overestimated or under-
estimated the results found here, since – by 
adopting such administration regimens – a 
total compliance with the administered treat-
ment was assumed, thus excluding the pres-
ence of cases of over- or under-consumption, 
contemplated instead for the actual spending.
The present analysis collected information 
only on the cART costs; other cost items were 
not considered (eg. hospitalizations, special-
ist visits, etc.), which however are potentially 
interesting for those wishing to examine in 
detail the knowledge of the resources re-
quired by HIV.
At last, a final limitation could be the repre-
sentativeness of these results on a national 
scale, since they are referred to a single cen-
ter located in Northern Italy. The verification 
of a possible variability of the data found 
here could be carried out only in the presence 
of similar analyses, conducted in other Italian 
geographic areas.
conclusIons
This observational analysis was carried out 
with the objective of estimating the financial 
impact of an optimization pathway of the 
antiretroviral therapy, aimed at maintaining 
its effectiveness over time. In light of the re-
sults presented, albeit with some limitations, 
it would seem possible to state that the op-
timization pathway proposed here is a valid 
therapeutic option in the maintenance treat-
ment of suppressed HIV-1 patients, since it 
can make sustainable the costs of the cART 
therapy currently charged to the Italian NHS, 
while ensuring the maintenance over time of 
adequate levels of effectiveness and safety.
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